Prevention of neutropenia during chemotherapy by prolonged myelostimulatory preparations

Птушкин, В. В.; Жуков, Н. В.; Borisov, Vasilii I.; Миненко, С. В.; Ларина, Ю В

doi:10.17650/1818-8346-2015-10-2-37-45

Cited by 2 publications

(3 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The most severe and dangerous form of neutropenia is febrile neutropenia (FN); in this state, the neutrophil count goes down to less than 0.5 × 10 9 /L. Patients with FN are treated with antibiotics (first line drugs) and hematopoietic cytokines [1,2].…”

Section: Introductionmentioning

confidence: 99%

“…Its recombinant analogues are a new class Abbreviations: PEG, polyethylene glycol; GCSF, human granu locyte colony stimulating factor; PEG GCSF, PEGylated GCSF; APS, active pharmaceutical substance; MP, medicinal product; IOC, ion exchange chromatography; HIC, hydropho bic interaction chromatography; GC, gel chromatography; FN, febrile neutropenia. 1 Corresponding author: phone/fax:+7 (916) 973 25 27; e mail: nvkononova@rambler.ru.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Recombinant granulocyte colony stimulating factor (filgrastim) of prolonged action: Optimization of conditions for extraction and purification from inclusion bodies

Kononova¹,

Yakovlev²,

Zhuravko³

et al. 2014

Russ J Bioorg Chem

View full text Add to dashboard Cite

We developed a unified process platform for two recombinant human GCSF medicines--one with the non-prolonged and the other with prolonged action. This unified technology led to a simpler and cheaper production while introduction of the additional pegylation stage to the technological line eased obtaining of the medicines with different action and allowed to standardize technological process documenting according to GMP requirements.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Recombinant granulocyte colony stimulating factor (filgrastim) of prolonged action: Optimization of conditions for extraction and purification from inclusion bodies

Kononova¹,

Yakovlev²,

Zhuravko³

et al. 2014

Russ J Bioorg Chem

View full text Add to dashboard Cite

show abstract

“…Neutropenia is one of the common reasons for reducing the relative dose intensity of che-motherapy. At the same time, it is fundamentally important to use full standard dose of cytostatics to achieve a positive clinical effect of chemotherapy [2]. Liposomal forms of cytostatics do not solve the problem of myelotoxicity.…”

mentioning

confidence: 99%

Advantages of the Liposomal Form of Xymedon in Leukopoiesis Restoration against the Background of Myelosuppressive Therapy with Liposomal Antineoplastic Drugs in Experiment

Solov'eva

Zemskova

2021

Bull Exp Biol Med

View full text Add to dashboard Cite

We analyzed advantages of the liposomal form of Xymedon (50 and 100 mg/kg) over free Xymedon (in the corresponding doses) in leukopoiesis restoration in rats with Walker-256 carcinoma treated with liposomal combination of doxorubicin (4 mg/kg) and cyclophosphamide (45 mg/kg) (single intravenous injection on day 11 after transplantation of tumor cells). Liposomal and free Xymedon were injected intravenously over 5 days starting from day 11 of the experiment. Changes in leukopoiesis in peripheral blood and myelograms were assessed on days 3 and 7 after chemotherapy. Liposomal Xymedon in both doses (unlike its free form) 2-fold increased the number of lymphocytes on day 3 after chemotherapy in comparison with the level observed after administration of liposomal cytostatics alone. Liposomal Xymedon in a dose of 50 mg/kg (but not 100 mg/kg) promoted the maintenance of monocyte count at the level of intact control on days 3 and 7 after chemotherapy. Liposomal Xymedon in a dose of 50 mg/kg and free Xymedon in a dose of 100 mg/kg equally stimulated the increase in myelocytes content in the bone marrow to the level of intact control on day 3 after chemotherapy, thus promoting restoration of granulocytopoiesis.

show abstract

Prevention of neutropenia during chemotherapy by prolonged myelostimulatory preparations

Cited by 2 publications

References 32 publications

Recombinant granulocyte colony stimulating factor (filgrastim) of prolonged action: Optimization of conditions for extraction and purification from inclusion bodies

Recombinant granulocyte colony stimulating factor (filgrastim) of prolonged action: Optimization of conditions for extraction and purification from inclusion bodies

Advantages of the Liposomal Form of Xymedon in Leukopoiesis Restoration against the Background of Myelosuppressive Therapy with Liposomal Antineoplastic Drugs in Experiment

Contact Info

Product

Resources

About